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ABSTRACT 
Objective: To assess the accuracy of first trimester soluble fms-like tyrosine kinase-1 (sFlt-1) and 
placental growth factor (PlGF) in predicting pregnancy hypertension and pre-eclampsia; and 
compare with the accuracy of routinely collected maternal and clinical risk factors. 
Study design: In this population-based cohort study, serum sFlt-1 and  PlGF levels were measured 
in first trimester in 2,681 women with singleton pregnancies in New South Wales, Australia.  
Main outcome measures: Prediction of pregnancy hypertension and pre-eclampsia.  
Results: There were 213 (7.9%) women with pregnancy hypertension, including 68 (2.5%) with 
pre-eclampsia. The area under the curve (AUC) for both sFlt-1 and PlGF was not different from 
chance, but combined was 0.55 (P=0.005). Parity and previous diagnosed hypertension had better 
predictive accuracy than serum biomarkers (AUC=0.64, P<0.001) and the predictive accuracy for 
all maternal and clinical information was fair (AUC=0.70, P<0.001 for pregnancy hypertension and 
AUC=0.74, P<0.001 for pre-eclampsia). Adding sFlt-1 and PlGF to maternal risk factors did not 
improve the ability of the models to predict pregnancy hypertension or pre-eclampsia. 
Conclusions: Maternal first trimester serum concentrations of sFlt-1 and PlGF do not predict 
hypertensive disorders in pregnancy any better than routinely collected clinical and maternal risk 
factor information. Screening for sFlt-1 and PlGF levels in early pregnancy would not identify those 
pregnancies at-risk. 
Key words: fms-like tyrosine kinase-1, placental growth factor, first trimester, pregnancy 
hypertension, pre-eclampsia, predictive accuracy 
 
 
 
 
 
 
 3 
INTRODUCTION 
Hypertensive disorders of pregnancy have a major impact on maternal health and are responsible 
for 9% - 25% of deaths worldwide [1] and encompass two different conditions. Chronic 
hypertension has onset prior to pregnancy or is diagnosed prior to 20 weeks gestation. Pregnancy 
hypertension has onset from 20 weeks gestation and ranges from hypertension alone (gestational 
hypertension) through proteinuria and multi-organ dysfunction (pre-eclampsia) to seizures 
(eclampsia). While these broad classifications are widely accepted, the diagnostic criteria for each 
subgroup vary internationally. Pregnancy hypertension and pre-eclampsia are of particular interest 
because if women at risk can be identified early in pregnancy this would allow ample time for 
monitoring and implementing preventive strategies.  
 
The pathogenesis of pre-eclampsia involves inadequate remodelling of spiral arteries during 
placental development [2], influenced by imbalances in expression of  pro-angiogenic factors such 
as placental growth factor (PlGF) and anti-angiogenic fms-like tyrosine kinase-1 (sFlt-1) receptor 
[3].   Serum concentrations of sFlt-1, PlGF and other biomarkers of placental development have 
been suggested to have predictive value along with several maternal and clinical risk factors that 
can also help identify women at-risk [4, 5]. However, results have come mostly from small studies 
[6], and have been inconsistent and not reliable enough for implementation in routine clinical 
practice. Evaluation of biomarkers for their clinical utility needs to assess the added benefit they 
offer to risks that can be ascertained from an antenatal booking history. The aim of this study was to 
assess the accuracy of first trimester fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor 
(PlGF), both alone and in combination, in predicting pregnancy hypertension and pre-eclampsia in a 
population-based cohort; and compare them with the accuracy of routinely collected maternal and 
clinical risk factors. 
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MATERIALS AND METHODS 
Study population and sample testing 
The study population included pregnant women attending first trimester Down syndrome screening 
between July and October 2006 in New South Wales (NSW), Australia. Serum samples were 
collected by the Pacific Laboratory Medicine Services (PaLMs), and then archived and stored at -80 
degrees Celsius. During this period this was the state’s only public screening service and received 
samples from throughout NSW.     
 
Serum samples for this study were thawed and serum levels of sFlt-1 were measured using a 
commercially available Quantikine ELISA kit (R&D Systems, Minneapolis, USA) while PlGF was 
measured by an automated immunoassay using commercially available kits (AutoDELFIA 
PerkinElmer Inc. Turku, Finland). Intra-assay and inter-assay coefficients of variation were <12% 
and the reported analytic sensitivity of the assay was 7.7 - 1980 pg/ml for sFlt-1 and 0.7 – 168 
pg/ml for PlGF. Laboratory scientists  were blinded to pregnancy outcomes. 
 
Data sources 
The laboratory database contained maternal information for those with archived serum samples and 
women’s corresponding pregnancy and birth outcomes were ascertained from the Perinatal Data 
Collection (PDC) and the Admitted Patient Data Collection (APDC), all three sources were then 
combined via record linkage. The PDC is a statutory surveillance system of all births in NSW of at 
least 400 grams birth weight, or at least 20 weeks gestation and includes demographic, medical and 
obstetric information on the mother, labour, delivery and birth outcomes.  The APDC is a census of 
all patient hospital admissions from NSW public and private hospitals, with records for both 
mothers and liveborn infants. It holds demographic, clinical and health services information for 
each admission. Relevant diagnoses and procedures are also recorded for each hospital admission 
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and coded according to the International Classification of Diseases version 10 – Australian 
Modification (ICD10-AM) and Australian Classification of Healthcare Interventions, respectively.  
 
In Australia unit record data from multiple datasets cannot be produced because unique identifiers 
are not available for record linkage.  Therefore, probabilistic linkage methods are used [7, 8]. This 
involves a complex process of blocking and matching combinations of selected variables (such as 
name, date of birth, address and hospital) using record-linkage software [9]. The validity of the 
probabilistic record linkage is extremely high with less than 1% of records having an incorrect 
match [8, 9]. Record linkage was conducted by The NSW Centre for Health Record Linkage 
(CHeReL) and identifying information are removed before the data are sent to researchers. The 
CHeReL assesses the linkage quality for each study, and for this study there were <5/1000 missed 
links and <2/1000 false positive links.  The study was approved by the NSW Population and Health 
Services Research Ethics Committee. 
 
Study outcomes included were pregnancy hypertension and pre-eclampsia and to maximize 
ascertainment, information was identified from both the APDC and PDC data [10, 11]. Pre-
eclampsia (regardless of severity) and any pregnancy hypertension (pre-eclampsia or gestational 
hypertension) were determined either if ‘Yes’ was recorded in response to the relevant questions 
(proteinuric or non proteinuric hypertension with onset >20 weeks) in the PDC record, or if any 
APDC record had a diagnosis of gestational hypertension (ICD10-AM: O13 and O16), pre-
eclampsia (O11 and O14) or eclampsia (O15) [11]. The key maternal and clinical risk factors used 
in this analysis included maternal age and weight (kilograms) ascertained at the time of first 
trimester screening, parity (nulliparous/multiparous), smoking during pregnancy, any previously 
diagnosed hypertension (chronic or pregnancy) or high blood pressure, any previously diagnosed 
diabetes (pre gestational or gestational), country of birth and socio-economic disadvantage quintile. 
Socio-economic disadvantage was determined using the Socio-Economic Indexes for Areas 
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(SEIFA) relative disadvantage scores developed by the Australian Bureau of Statistics (ABS) [12]. 
Information on Pregnancy Associated Plasma Protein A (PAPP-A) from laboratory data (used for 
Down syndrome screening) was also available for analysis. Only factors that are well and 
accurately reported were included in the analyses [13]. Maternal weight was missing in 570 (21%) 
of the records. Multiple imputation was used to account for the missing maternal weight, a 
technique that predicts missing values using existing values from other variables [14]. Other 
missing data were infrequent: there were no records with missing maternal age, parity, country of 
birth or socio-economic disadvantage. Smoking was missing in 29 records (1.1%) and there were 5 
missing records for PAPP-A (0.2%) which were excluded from the analysis.  
 
Statistical analysis 
Comparison of maternal characteristics and concentrations of sFlt-1 and PlGF between women with 
and without each clinical outcome was performed using contingency tables, student’s t-test or 
Wilcoxon-rank sum test for categorical, normal or non-normally distributed data, respectively. As 
sFlt-1 and PlGF varied by gestational age, weight and smoking status, levels were standardized 
using multiple of the median (MoM) as described by Cuckle and Wald [15]. Logarithmic 
transformation of sFlt-1 and PlGF MoM was used to produce Gaussian distributions.  
 
Univariate logistic regression analysis was performed to assess associations between serum 
biomarkers and adverse pregnancy outcomes. Multivariate logistic regression analysis was then 
conducted to evaluate serum biomarkers taking into account maternal factors identified in the 
literature to be associated with the outcomes of interest (parity, weight, previous diagnosis of any 
hypertension). Separate models were conducted, firstly evaluating just serum biomarkers alone, 
then serum biomarkers combined, then maternal and clinical factors only (excluding biomarkers) 
and finally a combined model including both serum biomarkers and maternal risk factors. Each of 
these models were compared to determine whether serum biomarker levels provided any additional 
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information to maternal and clinical risk factors in predicting pregnancy hypertension and pre-
eclampsia, by evaluating  the differences in maximum likelihood estimates from each model using 
the likelihood ratio test (X2). 
The diagnostic performance of the models was determined by examining the area under the 
Receiver Operating Characteristic (ROC) curves (AUC). A standardized scale was then used to 
assess the AUC results [16],  where an AUC of 1 represents a perfect test, 0.9 – <1 an excellent test, 
0.8 – <0.9 a good test, 0.7 – <0.8 a fair test, 0.6 – <0.7 a poor test and 0.5 – <0.6 a worthless test. 
AUC results were also examined to determine whether models performed better than chance (0.5). 
Finally, estimates of predictive accuracy at a fixed 5% false positive rate were calculated including 
sensitivity, specificity, positive (PPV), negative predictive values (NPV) and positive likelihood 
ratio with exact binominal confidence intervals. Models and predictive accuracy were examined 
among all women and for a sub-group of nulliparous women that have increased risk of pregnancy 
hypertension or pre-eclampsia [2, 5]. A P-value of <0.05 was considered to be statistically 
significant and analyses performed using SAS software 9.2 (SAS Institute Inc., Cary, NC, USA).  
 
RESULTS 
A total of 2,973 serum samples were tested for sFlt-1 and PlGF; with health information relevant to 
the pregnancy available for 2,782 (93.6%) samples. We excluded 101 women whose blood sample 
was taken before 10 or after 14 weeks gestation, had a medical abortion, had a twin pregnancy or 
had an infant with a major congenital anomaly. A total of 2,681 women were included in the 
analysis. Levels of sFlt-1 and PlGF were outside the limits of assay detection for 40 and 6 women, 
respectively. Table 1 presents the maternal characteristics and biomarker levels by pregnancy 
outcome. The mean (SD) maternal age was 32.8 (4.6) years, mean maternal weight was 66.9 (12.7) 
kg, 1,182 (44.8%) women were nulliparous and 162 (6.1%) smoked during pregnancy. Compared 
to unaffected pregnancies, women with pregnancy hypertension or pre-eclampsia were heavier, 
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were more likely to be having their first baby and to have been previously diagnosed with 
hypertension.   
 
Median [inter quartile range (IQR)] serum levels of sFlt-1 and PlGF for the total cohort were 286.4 
(167.1 – 466.8) pg/ml and 23.9 (18.1 – 31.5) pg/ml, respectively. There were 213 (7.9%) women 
diagnosed with pregnancy hypertension, including 68 (2.5%) with pre-eclampsia. Compared with 
unaffected pregnancies (median PlGF: 24.1, IQR: 18.3 – 31.7 pg/ml), median levels of PlGF in first 
trimester were significantly lower for women subsequently diagnosed with pregnancy hypertension 
(median PlGF 21.3, IQR: 16.9 - 28.0 pg/ml; P<0.001). Compared with unaffected pregnancies, 
women with pregnancy hypertension and pre-eclampsia had a tendency to have lower sFlt-1 levels, 
but differences were not significant (Table1). 
 
Figure 1 presents the distribution of log sflt-1 (MoM) and log PlGF (MoM) for women with and 
women without pregnancy hypertension and pre-eclampsia. There was no difference in the 
distribution of log PlGF and log sFlt-1 comparing women with and without pregnancy hypertension 
and pre-eclampsia. Table 2 presents the predictive accuracy results for pregnancy hypertension and 
pre-eclampsia for all women.  The area under the curve (AUC) for univariate models evaluating 
individual biomarkers was no different to chance, but for all three biomarkers combined, AUC was 
0.55 (P=0.005). Parity and previous diagnosed hypertension had better predictive accuracy than 
serum biomarkers (AUC=0.64, P<0.001) and predictive accuracy for all maternal and clinical 
information was fair (AUC=0.70, P<0.001 for pregnancy hypertension and AUC=0.74, P<0.001 for 
pre-eclampsia). Adding serum biomarkers to maternal risk factors did not improve the ability of the 
models to predict pregnancy hypertension or pre-eclampsia (X2=2.70, P=0.10 for GH; and X2=1.24, 
P=0.27 for pre-eclampsia).  
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Table 3 presents the predictive accuracy results for pregnancy hypertension and pre-eclampsia for 
nulliparous women only. The AUC results for individual biomarkers were similar compared to 
those for all women. Maternal weight had better predictive accuracy than serum biomarkers 
(AUC=0.61, P<0.001) and predictive accuracy of all maternal and clinical information was similar 
to all women (Table 3). Including serum biomarkers with maternal risk factors did not improve the 
ability of the models to predict pregnancy hypertension or pre-eclampsia (X2=3.00, P=0.08 for 
pregnancy hypertension; and X2=0.97, P=0.32 for pre-eclampsia) (Table 3). In analyses for all and 
for nulliparous women, the positive likelihood ratio results for maternal and clinical risk factors 
were superior, ranging between 4.09 and 5.25 (Tables 2 and 3). 
 
DISCUSSION 
This is one of the largest studies to investigate the accuracy of sFlt-1 and PlGF in early pregnancy 
in predicting pregnancy hypertension and pre-eclampsia. It also provides an important comparison 
of the utility of serum biomarkers with maternal and clinical risk factors. Although sFlt-1 and PlGF 
levels were generally lower among women subsequently diagnosed with pregnancy hypertension 
and pre-eclampsia, our results indicate that the predictive accuracies of first trimester serum 
concentrations of sFlt-1 and PlGF were insufficient in predicting these outcomes. Clinical and 
maternal risk factors had fair predictive accuracy and outperformed a combination of these first 
trimester serum biomarkers. Adding serum sFlt-1, PlGF and PAPP-A levels to risk factors did not 
improve the accuracy of models in predicting pregnancy hypertension and pre-eclampsia, even 
when limiting the analysis to nulliparous women.     
 
Consistent with most previous studies we found little or no difference in sFlt-1 or PlGF levels in 
first trimester between women with and without subsequent pre-eclampsia [3, 17-22]; and poor 
accuracy in predicting any pre-eclampsia or pre-eclampsia >34 weeks [23-25]. This includes a large 
population-based prospective cohort study of 7,519 women, highlighting little association and no 
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potential predictive ability between sFlt-1 or PlGF and pre-eclampsia [3]. In contrast, three studies 
reported a potential utility of sFlt-1 or PlGF levels in first trimester for predicting any pre-eclampsia 
or pre-eclampsia <34 weeks (based on a 10% fixed false positive rate, sensitivity ranging between 
0.33 and 0.58 and AUC between 0.65 and 0.83, respectively) [26-28]. Promising results have been 
also reported for PlGF in predicting early (<34 weeks) or severe pre-eclampsia (based on a 5% 
fixed false positive rate, sensitivity: 0.28 - 0.30; AUC: 0.75 - 0.80, respectively) [26, 29, 30], 
however, we could not assess the accuracy for this outcome due to the low number of cases in our 
cohort. The accuracy of sFlt-1 and PlGF alone in predicting pre-eclampsia in nulliparous women 
has been investigated by three other studies [30-32], in addition to ours. In all studies, results for 
sFlt-1 were comparable with ours, but in other studies PlGF performed better in predicting pre-
eclampsia in this sub-group of women. The studies reported an AUC for PlGF in predicting any 
pre-eclampsia ranging between 0.61 and 0.65 [30, 31] and an AUC of 0.77 for pre-eclampsia <37 
weeks [32]. Factors that may influence variation in predictive accuracy results and biomarker 
concentrations include the timing of the sampling, timing of the onset of disease and whether levels 
were standardized or not to MoM values. 
 
The main issue attributed to the lack of predictive ability of sFlt-1 and PlGF in early pregnancy is 
that imbalances between pro and anti angiogenic factors involved in the pathogenesis of pre-
eclampsia, may not be expressed until later in pregnancy. Longitudinal studies of serum sFlt-1 and 
PlGF [3, 20, 22, 24] have demonstrated that the association of levels with pre-eclampsia strengthens 
with the course of pregnancy, but that these would not be clinically useful in predicting pre-
eclampsia until third trimester [24]. Furthermore, better predictive accuracy has been reported with 
testing in second trimester [33], but screening at 2nd or 3rd trimester may be too late for preventive 
interventions to be effective.  The potential advantages of first trimester screening include the 
opportunity to incorporate an additional test into existing, routine antenatal testing for identification 
of at-risk pregnancies for closer surveillance. In addition, early implementation of dietary and 
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lifestyle interventions [34] or low-dose aspirin [35] in these pregnancies, may reduce the risk of pre-
eclampsia. 
 
Compared with serum biomarker information alone, we found maternal and clinical risk factors, 
specifically parity, previously diagnosed hypertension and maternal weight provide greater 
predictive value. And, when sFlt-1 or PlGF information is added to these combined, neither 
biomarker provided any additional predictive information. In other studies, the addition of PlGF to 
maternal risk factors improves the predictive accuracy, but the significance of this was not reported 
(relative increase in AUC ranging between 5% and 16%) [26, 30-32]. Although, our LR results for 
clinical risk factors revealed these would be three to five times more likely to be present in women 
with, as opposed to women without, pregnancy hypertension or pre-eclampsia, these LR values are 
still only considered to be indicative of a relatively small likelihood of disease [36]. A systematic 
review of risk factors for pre-eclampsia revealed that there are a broad range of other important risk 
factors that are also important to be taken into account, but we did not have information on, such as 
the presence of antiphospholipid antibodies or family history of hypertension [5].  Overall, our 
results highlight that complete maternal risk factor information compared with any serum biomarker 
tested in early pregnancy would potentially provide much better information in predicting 
hypertensive disorders in pregnancy.  
 
Some of the potential limitations of the study include the lower prevalence of pre-eclampsia (2.5%) 
compared with the maternity population in NSW (3.1%) [37] which may be due to a healthier and 
more affluent cohort. Maternal weight was missing in 21% of the women, although this was 
addressed by applying multiple imputations, which has shown to be a robust and valid technique for 
dealing with missing data [14]. Despite these, strengths of this study were the assessment of an 
unselected consecutive cohort of women attending first trimester screening. Record linkage of 
laboratory to birth and hospital data also ensured follow up and ascertainment of pregnancy 
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outcomes with only minimal missing information. Missing health and pregnancy information was 
mostly attributable to women giving birth in hospitals out of state, although, these women had 
similar characteristics compared with those included in the study.   
 
In conclusion, our findings suggest that maternal first trimester serum concentrations of sFlt-1 and 
PlGF do not predict pregnancy hypertension and pre-eclampsia any better than routinely assessed 
clinical and maternal risk factor information. Screening for sFlt-1 and PlGF levels in early 
pregnancy would not predict those pregnancies at-risk. 
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Table 1: Demographic characteristics and serum levels of PlGF, sFlt-1 and PAPP-A                        
of the study population by pregnancy outcome  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a P<0.05; b P<0.001; SD: Standard deviation; MoM: Multiple of the median; IQR: Interquartile range 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Unaffected women      n=2,468 
Pregnancy 
Hypertension     
n=213 
Pre-eclampsia      
n=68 
Age (SD) 32.8 (4.7) 32.6 (4.3) 32.1 (4.1) 
Maternal Weight (SD) 66.3 (13.7) 74.4 (18.0) b 72.8 (16.8)b 
Smoking (%) 150 (6.2) 12 (5.6) 1 (1.5) 
Nulliparous (%) 1064 (43.9) 118 (55.7) b 44 (65.7)b 
Country of Birth (%)    
Australia & New 
Zealand 1641 (66.5) 180 (84.5)
 b 50 (73.5) 
Asian countries 322 (13.1) 11 (5.2) b 6 (8.8) 
Other countries 505 (20.5) 22 (10.3) b 12 (17.7) 
Previously diagnosed 
hypertension (%) 139 (15.6) 40 (18.8)
 b 11 (16.2) b 
Previously diagnosed 
diabetes (%) 61 (2.5) 11 (5.2) 
a 4 (5.9) 
PlGF pg/ml (IQR) 24.1 (18.3, 31.7) 21.3 (16.9, 28.0) b 20.7 (17.2, 32.6) 
sFlt-1 pg/ml (IQR) 286.8 (167.1, 472.1) 272 (169.6, 441.7) 268.1 (164.8, 390.5) 
PAPP-A pg/ml (IQR) 1.71 (1.06, 2.79) 1.41 (0.80, 2.14) b 1.34 (0.76, 2.4) a 
PlGF MoM (IQR) 1.01 (0.77, 1.31) 0.92 (0.71, 1.24) b 0.92 (0.73, 1.31) 
sFlt-1 MoM (IQR) 1.01 (0.60, 1.67) 1.01 (0.62, 1.56) 0.82 (0.53, 1.46) 
PAPP-A MoM (IQR) 0.98 (0.66, 1.46) 0.94 (0.62, 1.37) 0.83 (0.57, 1.32) 
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Table 2: Accuracy of models using serum biomarkers levels and maternal and clinical information in                                                                           
early pregnancy to predict pregnancy hypertension and pre-eclampsia based on a 5% false positive rate in all women 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Including: Maternal weight, smoking during pregnancy, parity, previously diagnosed hypertension, previously diagnosed diabetes, high blood pressure  
recorded during pregnancy and country of birth; PPV: Positive likelihood ratio; NPV: Negative predictive value; LR: Likelihood ratio; MoM: Multiple of the median
Variable  AUC (95%CI) P-value Sensitivity (%) (95%CI) 
PPV (%) 
(95%CI) 
NPV (%) 
(95%CI) 
LR 
(+) 
(N=2,681) 
Pregnancy hypertension (n=213)       
PlGF MoM 0.56 (0.52, 0.60) 0.005 6.1 (3.3, 10.3) 9.6 (5.2, 15.8) 92.2 (91.0, 93.2) 1.23 
sFlt-1 MoM 0.52 (0.48, 0.55) 0.4 5.8 (3.0, 9.9) 9.0 (4.7, 15.2) 92.2 (91.1, 93.2) 1.17 
PAPP-A MoM 0.53 (0.49, 0.57) 0.15 7.5 (4.4, 11.9) 11.8 (6.9, 18.4) 92.2 (91.1, 93.3) 1.54 
Serum Biomarkers only 0.55 (0.51, 0.58) 0.005 6.3 (3.4, 10.5) 9.7 (5.3, 16.0) 92.3 (91.2, 93.3) 1.26 
Previously diagnosed hypertension + 
Parity 0.64 (0.60, 0.67) <0.0001 18.0 (13.0, 23.9) 21.5 (15.6, 28.4) 93.0 (91.9, 94.0) 3.17 
All maternal and clinical 
information*  0.70 (0.67, 0.74) <0.0001 26.2 (20.3, 32.8) 31.2 (24.4, 38.7) 93.7 (92.7, 94.6) 5.25 
Combined – biomarkers + maternal 
and clinical information 0.70 (0.67, 0.74) <0.0001 24.8 (19.0, 31.2) 30.0 (23.2, 37.5) 93.6 (92.5, 94.5) 4.96 
Pre-eclampsia (n=68)       
PlGF MoM 0.52 (0.45, 0.60) 0.5 7.4 (2.4, 17.3) 3.7 (1.2, 8.4) 97.5 (96.8, 98.1) 1.47 
sFlt-1 MoM 0.56 (0.49, 0.62) 0.1 5.9 (1.6, 14.4) 3.0 (0.8, 7.6) 97.5 (96.8, 98.0) 1.18 
PAPP-A MoM 0.57 (0.49, 0.64) 0.07 8.8 (3.3, 18.2) 4.4 (1.6, 9.4) 97.6 (96.9, 98.1) 1.77 
Serum Biomarkers only 0.57 (0.50, 0.65) 0.04 7.4 (2.4, 16.3) 3.8 (1.2, 8.6) 97.5 (96.8, 98.1) 1.77 
Previously diagnosed hypertension + 
Parity 0.66 (0.60, 0.72) <0.0001 16.2 (8.4, 27.1) 6.4 (3.2, 11.2) 97.6 (97.0, 98.2) 2.53 
All maternal and clinical 
information* 0.74 (0.68, 0.80) <0.0001 25.0 (15.3, 37.0) 12.0 (7.1, 18.5) 97.9 (97.3, 98.4) 5.03 
Combined – biomarkers + maternal 
and clinical information 0.76 (0.70, 0.82) <0.0001 25.0 (15.3, 37.0) 12.0 (7.1, 18.5) 97.9 (97.3, 98.4) 5.03 
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Table 3: Accuracy of models using serum biomarkers levels and maternal and clinical information in                                                                          
early pregnancy to predict pregnancy hypertension based on a 5% false positive rate in nulliparous women 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Including: Maternal weight, smoking during pregnancy, parity, previously diagnosed hypertension, previously diagnosed diabetes, high blood pressure  
recorded during pregnancy and country of birth; PPV: Positive likelihood ratio; NPV: Negative predictive value; LR: Likelihood ratio; MoM: Multiple of the median
Variable  AUC (95%CI) P-value Sensitivity (%) (95%CI) 
PPV (%) 
(95%CI) 
NPV (%) 
(95%CI) 
LR 
(+) 
(N=1,182) 
Pregnancy hypertension (n=118)             
PlGF MoM 0.57 (0.51, 0.63) 0.02 6.0 (2.4, 11.9) 11.5 (4.4, 22.2) 90.3 (88.5, 92.0) 1.20 
sFlt-1 MoM 0.52 (0.46, 0.57) 0.5 5.3 (2.0, 11.2) 10.2 (3.8, 20.8) 90.5 (88.6, 92.1) 1.07 
PAPP-A MoM 0.54 (0.49, 0.60) 0.11 6.8 (3.0, 12.9) 12.1 (5.4, 22.5) 90.3 (88.4, 92.0) 1.26 
Serum Biomarkers only 0.57 (0.52, 0.63) 0.01 4.4 (1.5, 10.0) 8.5 (2.8, 18.7) 90.4 (88.5, 92.0) 0.87 
Maternal weight 0.61 (0.55, 0.67) 0.0001 19.5 (12.8, 27.8) 29.9 (20.0, 41.4) 91.6 (89.8, 93.1) 3.92 
All maternal and clinical information 
only* 0.68 (0.63, 0.74) <0.0001 25.6 (18.0, 34.5) 36.1 (25.9, 47.4) 92.1 (90.3, 93.6) 5.16 
Combined – biomarkers + maternal 
and clinical information 0.70 (0.65, 0.75) <0.0001 26.8 (18.9, 36.0) 36.1 (25.9, 47.4) 92.4 (90.7, 93.9) 5.31 
Pre-eclampsia (n=44)       
PlGF MoM 0.49 (0.39, 0.59) 0.9 9.1 (2.5, 21.7) 6.5 (1.8, 15.7) 96.5 (95.2, 97.5) 1.81 
sFlt-1 MoM 0.58 (0.49, 0.66) 0.07 9.1 (2.5, 21.7) 6.6 (1.8, 15.9) 96.4 (95.2, 97.4) 1.82 
PAPP-A MoM 0.54 (0.45, 0.63) 0.3 11.4 (3.8, 24.6) 7.6 (2.5, 16.8) 96.6 (95.3, 97.5) 2.15 
Serum Biomarkers only 0.58 (0.49, 0.67) 0.07 11.4 (3.8, 24.6) 8.1 (2.7, 17.8) 96.5 (95.3, 97.5) 2.26 
Maternal weight 0.63 (0.55, 0.71) 0.002 18.2 (8.2, 32.7) 12.1 (5.4, 22.5) 96.8 (95.6, 97.8) 3.63 
All maternal and clinical information 
only* 0.71 (0.64, 0.78) <0.0001 20.5 (9.8, 35.3) 13.6 (6.4, 24.3) 96.9 (95.7, 97.8) 4.09 
Combined – biomarkers + maternal 
and clinical information 0.74 (0.66, 0.81) <0.0001 25.0 (13.2, 40.3) 16.4 (8.5, 27.5) 97.0 (95.8, 97.9) 4.99 
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Figure 1: Comparison of log sFlt-1 MoM and log PlGF MoM distributions in affected and unaffected pregnancies for pregnancy hypertension 
and pre-eclampsia 
